SCHEMBL17645216

SCHEMBL17645216

Nc1c[nH]nc1Oc1ccccn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.39
▸ PIN1 Q13526 1/20 0.38
▸ NOS3 P29474 1/20 0.36
▸ NOS1 P29475 1/20 0.36
▸ NOS2 P35228 1/20 0.36
▸ PI4KA P42356 1/20 0.36
▸ PI4K2B Q8TCG2 1/20 0.36
▸ PI4K2A Q9BTU6 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ GRM4 Q14833 2/20 0.36
▸ LMNA P02545 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CCR1 P32246 1/20 0.34
▸ CCR5 P51681 1/20 0.34
▸ CCR8 P51685 1/20 0.34
▸ METAP1 P53582 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ HIF1A Q16665 1/20 0.34
▸ DOHH Q9BU89 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16200215 0.79 GRM4 (0.46) KDM4EPIN1GRM4LMNACYP1A2
SCHEMBL1705163 0.77 KDM4E (0.46) KDM4EPIN1NOS3NOS1NOS2
SCHEMBL409030 0.72 KDM4E (0.55) KDM4EPIN1NOS3NOS1NOS2
SCHEMBL7874577 0.71 KDM4E (0.56) KDM4EPIN1NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL9650595 0.70 GRM4 (0.39) KDM4EPIN1NOS3NOS1NOS2
Hydrochloric Acid SCHEMBL28670387 0.70 KDM4E (0.53) KDM4EPIN1NOS3NOS1NOS2
Phosphine SCHEMBL17979775 0.70 KDM4E (0.53) KDM4EPIN1NOS3NOS1NOS2
Ethylene SCHEMBL27741856 0.68 KDM4E (0.52) KDM4EPIN1NOS3NOS1NOS2
SCHEMBL4379584 0.67 MEN1 (0.62) KDM4EPOLBMAP4K4LTA4HPTGS2
SCHEMBL1817017 0.67 KDM4E (0.43) KDM4EPIN1GRM4LMNACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812105-B Aminopyridyloxy pyrazole derivative, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2025-04-01 — — CN claimed
CN-112812105-A Aminopyridyloxypyrazole derivative and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-05-18 — — CN claimed
CN-112812105-B Aminopyridyloxy pyrazole derivative, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2025-04-01 — — CN disclosed
CN-112812105-B Aminopyridyloxy pyrazole derivative, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2025-04-01 — — CN disclosed
CN-112812105-B Aminopyridyloxy pyrazole derivative, and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2025-04-01 — — CN disclosed
US-20220107328-A1 METHODS OF TREATING LIVER DISEASES CAMP4 THERAPEUTICS CORPORATION 2022-04-07 — — US disclosed
EP-3836929-A1 METHODS OF TREATING LIVER DISEASES Camp4 Therapeutics Corporation (US) 2021-06-23 — — EP disclosed
CN-112812105-A Aminopyridyloxypyrazole derivative and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-05-18 — — CN disclosed
CN-112812105-A Aminopyridyloxypyrazole derivative and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-05-18 — — CN disclosed
CN-112812105-A Aminopyridyloxypyrazole derivative and preparation method and application thereof 苏州阿尔脉生物科技有限公司 2021-05-18 — — CN disclosed
US-20200208128-A1 METHODS OF TREATING LIVER DISEASES CAMP4 THERAPEUTICS CORPORATION 2020-07-02 — — US disclosed
EP-3204377-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS Eli Lilly and Company (US) 2017-08-16 — — EP disclosed
EP-3204377-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS Eli Lilly and Company (US) 2017-08-16 — — EP disclosed
US-9617243-B2 Aminopyridyloxypyrazole compounds ELI LILLY AND COMPANY (US) 2017-04-11 — — US disclosed
US-9617243-B2 Aminopyridyloxypyrazole compounds ELI LILLY AND COMPANY (US) 2017-04-11 — — US disclosed
US-9617243-B2 Aminopyridyloxypyrazole compounds ELI LILLY AND COMPANY (US) 2017-04-11 — — US disclosed
WO-2016057278-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS ELI LILLY AND COMPANY (US) 2016-04-14 — — WO disclosed
WO-2016057278-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS ELI LILLY AND COMPANY (US) 2016-04-14 — — WO disclosed
US-20160096823-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS LILLY CO ELI (US) 2016-04-07 — — US disclosed
US-20160096823-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS LILLY CO ELI (US) 2016-04-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200208128-A1 METHODS OF TREATING LIVER DISEASES LIPC, PNPLA2, PNLIP KDM4E 2781/4885PIN1 3751/4885NOS3 153/4885
US-20220107328-A1 METHODS OF TREATING LIVER DISEASES PNPLA2, LIPC, PNLIP KDM4E 2911/4885PIN1 4020/4885NOS3 539/4885
US-20160096823-A1 AMINOPYRIDYLOXYPYRAZOLE COMPOUNDS TGFBR1, TGFBR2, PDGFRB KDM4E 2430/4885PIN1 3928/4885NOS3 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback